Compare ZURA & AHRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | AHRT |
|---|---|---|
| Founded | 2022 | 1979 |
| Country | United States | United States |
| Employees | 40 | 98 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 501.3M |
| IPO Year | N/A | 2013 |
| Metric | ZURA | AHRT |
|---|---|---|
| Price | $3.71 | $6.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $13.00 | $7.00 |
| AVG Volume (30 Days) | 856.3K | ★ 907.5K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 9.30% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $854.92 |
| Revenue Next Year | N/A | $11.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $5.13 |
| 52 Week High | $7.25 | $6.98 |
| Indicator | ZURA | AHRT |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 64.49 |
| Support Level | $3.25 | $6.59 |
| Resistance Level | $4.12 | N/A |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 39.50 | 72.15 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.